These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32187543)

  • 1. Machine Learning Uncovers Food- and Excipient-Drug Interactions.
    Reker D; Shi Y; Kirtane AR; Hess K; Zhong GJ; Crane E; Lin CH; Langer R; Traverso G
    Cell Rep; 2020 Mar; 30(11):3710-3716.e4. PubMed ID: 32187543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
    Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
    Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.
    Hochman JH; Yamazaki M; Ohe T; Lin JH
    Curr Drug Metab; 2002 Jun; 3(3):257-73. PubMed ID: 12083320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excipient-drug pharmacokinetic interactions: Effect of disintegrants on efflux across excised pig intestinal tissues.
    Gerber W; Hamman JH; Steyn JD
    J Food Drug Anal; 2018 Apr; 26(2S):S115-S124. PubMed ID: 29703379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of expression/function of intestinal P-glycoprotein under disease states.
    Murakami T; Bodor E; Bodor N
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
    [No Abstract]   [Full Text] [Related]  

  • 6. A regulatory viewpoint on transporter-based drug interactions.
    Zhang L; Zhang YD; Strong JM; Reynolds KS; Huang SM
    Xenobiotica; 2008 Jul; 38(7-8):709-24. PubMed ID: 18668428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Inactive" excipients such as Cremophor can affect in vivo drug disposition.
    Wandel C; Kim RB; Stein CM
    Clin Pharmacol Ther; 2003 May; 73(5):394-6. PubMed ID: 12732839
    [No Abstract]   [Full Text] [Related]  

  • 8. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
    Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
    Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in silico prediction of P-glycoprotein-mediated transport for 2010-2020 US FDA-approved drugs using six Web-tools.
    Guéniche N; Huguet A; Bruyere A; Habauzit D; Le Hégarat L; Fardel O
    Biopharm Drug Dispos; 2021 Sep; 42(8):393-398. PubMed ID: 34272891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
    Tachibana T; Kato M; Takano J; Sugiyama Y
    Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
    Elsby R; Surry DD; Smith VN; Gray AJ
    Xenobiotica; 2008 Jul; 38(7-8):1140-64. PubMed ID: 18668443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review.
    Sosnik A
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1828-51. PubMed ID: 24055628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excipient knowledgebase: Development of a comprehensive tool for understanding the disposition and interaction potential of common excipients.
    McFeely SJ; Yu J; Wang Y; Wu C; Ragueneau-Majlessi I
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):953-961. PubMed ID: 34102029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
    Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
    J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.
    Dantzig AH; de Alwis DP; Burgess M
    Adv Drug Deliv Rev; 2003 Jan; 55(1):133-50. PubMed ID: 12535578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
    Patel J; Mitra AK
    Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excipient-drug interactions in parenteral formulations.
    Akers MJ
    J Pharm Sci; 2002 Nov; 91(11):2283-300. PubMed ID: 12379914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of drug metabolizing enzymes and transporters in the cochlea: Implications for drug delivery and ototoxicity.
    Kennon-McGill S; Clemens MM; McGill MR
    Hear Res; 2019 Aug; 379():98-102. PubMed ID: 31121337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking.
    Kadioglu O; Efferth T
    Cells; 2019 Oct; 8(10):. PubMed ID: 31640190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Excipients and Drug Metabolism: A Mini-Review.
    Patel R; Barker J; ElShaer A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.